MET Targeted Therapy for NSCLC
Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI
2
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
3
Investigational Mitochondrial Agent Shows Early Survival Signal in Glioblastoma
4
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
5